Asia
Vygon Asia announces that it has donated 50 Vygon Polysite ISP implantable ports for patients undergoing chemotherapy at the Mount Miriam Cancer Hospital under the One Port One Life program.
The two companies will pair CStone’s CS1001 with Bayer’s regorafenib, an oral multi-kinase inhibitor that targets VEGFR, FGFR, CSF1R and other receptors.
Here’s a look at some of last week’s clinical trial announcements, including some from the American Society of Clinical Oncology Annual Meeting you might have missed.
The fixed-dose combination was being evaluated in adults with intermediate and high-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Gavi, the Vaccine Alliance, NEC Corporation, and Simprints Technology Ltd. have signed a memorandum of understanding on the use of biometrics to improve immunization coverage in developing countries.
Takeda said that patients treated with Ninlaro in the Phase III TOURMALINE-AL1 study failed to see a significant improvement in overall hematologic response.
Novel technique enables simultaneous production of molybdenum-99 and other isotopes without the need for highly enriched, weapons grade uranium
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, announced that it starts exclusive sales of NeuroStar® Transcranial Magnetic Stimulation in 5 June, which was first listed under coverage of Japanese national health insurance as the TMS device for depression on 1 June.
EpimAb plans to use the funds to advance its Phase I/II clinical program, EMB01, expand its clinical pipeline into immuno-oncology and other areas and add a new manufacturing site in Suzhou for process development and pilot manufacturing.
Great Bay Bio announced its formal establishment in Hong Kong and the Chairman, Mr. Kingsley Leung is pleased to appoint Mr. Michael Chan as CEO and co-founder of the company on behalf of the board.
PRESS RELEASES